Literature DB >> 20074469

Idiopathic recurrent pericarditis refractory to colchicine treatment can reveal tumor necrosis factor receptor-associated periodic syndrome.

L Cantarini1, O M Lucherini, R Cimaz, C T Baldari, F Bellisai, S Rossi Paccani, F Laghi Pasini, P L Capecchi, G D Sebastiani, M Galeazzi.   

Abstract

Recurrences develop in up to 20-50% of patients with acute pericarditis. Although different causes of recurrent pericarditis have been identified, the etiology remains obscure in most cases which are therefore labelled as idiopathic. Autoinflammatory syndromes include familial Mediterranean fever (FMF), due to mutations in the MEFV gene, and tumor necrosis factor receptor-associated periodic syndrome (TRAPS), due to mutations in the TNFRSF1A gene. Recurrent pericarditis is a common feature of both conditions, but it rarely occurs alone. Colchicine is the standard treatment for FMF, while patients with TRAPS do not respond to colchicine therapy, but are responsive to corticosteroids. Based on the proven efficacy of colchicine in preventing polyserositis in FMF, colchicine has been proposed for the treatment of recurrent pericarditis and is able to decrease the recurrence rate. Our aim was to investigate the possible involvement of TNFRSF1A mutations in a group of patients with idiopathic recurrent pericarditis who were refractory to colchicine treatment. Thirty consecutive patients (17 males, 13 females) diagnosed with idiopathic recurrent pericarditis, who were characterized by a poor response to colchicine treatment, were enrolled in the study. Mutations of the TNFRSF1A gene were searched for by amplifying, using polymerase chain reaction (PCR), genomic DNA, and direct sequencing. TNFRSF1A mutations were found in 4 of the 30 patients. None of these 4 patients had a family history of recurrent inflammatory syndromes or history of pericarditis. One of the 4 patients had a novel heterozygous deletion (DeltaY103-R104) and three patients carried a heterozygous low-penetrance R92Q mutation. Our data suggest that TRAPS should be kept in mind in the differential diagnosis of recurrent pericarditis, and mutation analysis of the TNFRSF1A gene should be considered, in addition to MEFV analysis, in patients of Mediterranean origin. A poor response to colchicine treatment and/or a steroid-dependence may be the clue to investigate TNFRSF1A mutations in patients with idiopathic recurrent pericarditis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20074469     DOI: 10.1177/039463200902200421

Source DB:  PubMed          Journal:  Int J Immunopathol Pharmacol        ISSN: 0394-6320            Impact factor:   3.219


  26 in total

1.  Autoinflammatory disorders and patients with isolated serosal involvement.

Authors:  Luca Cantarini; Orso Maria Lucherini; Rolando Cimaz; Maria Giuseppina Brizi; Mauro Galeazzi
Journal:  Rheumatol Int       Date:  2010-05-22       Impact factor: 2.631

2.  Clues to detect tumor necrosis factor receptor-associated periodic syndrome (TRAPS) among patients with idiopathic recurrent acute pericarditis: results of a multicentre study.

Authors:  Luca Cantarini; Orso Maria Lucherini; Antonio Brucato; Luca Barone; Davide Cumetti; Francesca Iacoponi; Donato Rigante; Giovanni Brambilla; Silvana Penco; Maria Giuseppina Brizi; Maria Cristina Patrosso; Guido Valesini; Bruno Frediani; Mauro Galeazzi; Rolando Cimaz; Giuseppe Paolazzi; Antonio Vitale; Massimo Imazio
Journal:  Clin Res Cardiol       Date:  2012-02-05       Impact factor: 5.460

Review 3.  The labyrinth of autoinflammatory disorders: a snapshot on the activity of a third-level center in Italy.

Authors:  Luca Cantarini; Antonio Vitale; Orso Maria Lucherini; Caterina De Clemente; Francesco Caso; Luisa Costa; Giacomo Emmi; Elena Silvestri; Flora Magnotti; Maria Cristina Maggio; Eugenia Prinzi; Giuseppe Lopalco; Bruno Frediani; Rolando Cimaz; Mauro Galeazzi; Donato Rigante
Journal:  Clin Rheumatol       Date:  2014-06-24       Impact factor: 2.980

Review 4.  Canakinumab efficacy and long-term tocilizumab administration in tumor necrosis factor receptor-associated periodic syndrome (TRAPS).

Authors:  Francesco La Torre; Maurizio Muratore; Antonio Vitale; Fulvio Moramarco; Laura Quarta; Luca Cantarini
Journal:  Rheumatol Int       Date:  2015-06-06       Impact factor: 2.631

5.  TNFRSF1A [corrected] R92Q mutation, autoinflammatory symptoms and multiple sclerosis in a cohort from Argentina.

Authors:  Marcelo A Kauffman; Dolores Gonzalez-Morón; Orlando Garcea; Andrés María Villa
Journal:  Mol Biol Rep       Date:  2011-05-13       Impact factor: 2.316

6.  Role of tumour necrosis factor (TNF)-α and TNFRSF1A R92Q mutation in the pathogenesis of TNF receptor-associated periodic syndrome and multiple sclerosis.

Authors:  A Caminero; M Comabella; X Montalban
Journal:  Clin Exp Immunol       Date:  2011-12       Impact factor: 4.330

7.  Large pericardial effusion in a family with recurrent pericarditis: A report of probable x-linked transmission.

Authors:  Stefano Maggiolini; Gianluca Tiberti; Luca Cantarini; Claudio Carbone; Silvana Mariani; Felice Achilli; Silvia Maestroni; Antonio Brucato
Journal:  Exp Clin Cardiol       Date:  2011

Review 8.  Cardiovascular disease in patients with autoinflammatory syndromes.

Authors:  Rainer Hintenberger; Agnes Falkinger; Kathrin Danninger; Herwig Pieringer
Journal:  Rheumatol Int       Date:  2017-11-01       Impact factor: 2.631

Review 9.  Key facts and hot spots on tumor necrosis factor receptor-associated periodic syndrome.

Authors:  Donato Rigante; Giuseppe Lopalco; Antonio Vitale; Orso Maria Lucherini; Caterina De Clemente; Francesco Caso; Giacomo Emmi; Luisa Costa; Elena Silvestri; Laura Andreozzi; Florenzo Iannone; Mauro Galeazzi; Luca Cantarini
Journal:  Clin Rheumatol       Date:  2014-06-17       Impact factor: 2.980

Review 10.  Recurrent pericarditis: new and emerging therapeutic options.

Authors:  Massimo Imazio; George Lazaros; Antonio Brucato; Fiorenzo Gaita
Journal:  Nat Rev Cardiol       Date:  2015-08-11       Impact factor: 32.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.